TY - JOUR. T1 - Laparoscopy versus laparotomy for the management of early stage endometrial cancer.. AU - Galaal, Khadra. AU - Bryant, Andrew. AU - Fisher, Ann D.. AU - Al-Khaduri, Maha. AU - Kew, Fiona. AU - Lopes, Alberto D.. PY - 2012. Y1 - 2012. N2 - Traditionally, surgery for endometrial cancer (hysterectomy with removal of both fallopian tubes and ovaries) is performed through laparotomy. It has been suggested that the laparoscopic approach is associated with a reduction in operative morbidity. Over the last 10 to 15 years there has been a steady increase of laparoscopy for endometrial cancer. This review investigates the evidence of benefits and harms of laparoscopic surgery compared with laparotomy for presumed early stage endometrial cancer. To compare the overall survival (OS) and disease-free survival (DFS) for laparoscopic surgery versus laparotomy in women with presumed early stage endometrial cancer. We searched the Cochrane Gynaecological Cancer Group Trials Register, Cochrane ...
Endometrial cancer is the most common malignancy of the female reproductive tract. The majority of patients with endometrial cancer are diagnosed at an early stage and cured with surgery with or without adjuvant radiotherapy. However, a significant number of patients present with metastatic disease outside of the pelvis or develop recurrent disease after primary therapy.. mTOR inhibitors have been shown to be promising agents in reducing tumor growth in vitro and in vivo, in several solid cancers. Inhibitors of mTOR are primarily cytostatic in cancer cells; combination therapy with cytotoxic chemotherapeutics and other biologic agents may prove to be the most advantageous use of these drugs. mTOR inhibition with a rapamycin analogue demonstrated in vitro antiproliferative activity on endometrial AN3 CA and HEC-1-A tumor cells, and this inhibition of proliferation was found to be concentration dependent. Topotecan is an active agent in the treatment of advanced and recurrent endometrial cancers. ...
We evaluated the efficacy and safety of the aromatase inhibitor exemestane in patients with advanced, persistent or recurrent endometrial carcinoma. We performed an open-label one-arm, two-stage, phase II study of 25 mg of oral exemestane in 51 patients with advanced (FIGO stage III-IV) or relapsed endometrioid endometrial cancer. Patients were stratified into subsets of estrogen receptor (ER) positive and ER negative patients. Recruitment to the ER negative group was stopped prematurely after 12 patients due to slow accrual. In the ER positive patients, we observed an overall response rate of 10%, and a lack of progression after 6 months in 35% of the patients. No responses were registered in the ER negative patients, and all had progressive disease within 6 months. For the total group of patients, the median progression free survival (PFS) was 3.1 months (95% CI: 2.0-4.1). In the ER positive patients the median PFS was 3.8 months (95% CI: 0.7-6.9) and in the ER negative patients it was 2.6 months (95%
One-carbon metabolism dietary factors, including levels of folate, choline, methionine, vitamin B2, vitamin B6 or vitamin B12, do not effect the endometrial incidence(4). But in Type I and II endometrial cancer study, intake of use of supplements containing folate and vitamins B2, B6, and B12 was associated with an increased risk of type II endometrial cancer.(5). The Folate (FOL) mediated poly-lactide-co-glycolide-polyethylene glycol nanoparticles (FOL-PEG-PLGA NPs) bearing paclitaxel (PTX), was found to be effective in indcution of cytotoxicity against HEC-1A cancer cells in vitro and in vivo, through possibly induced apoptosis(6). The joint study of the effects of dietary folate and other methyl-related nutrients, as well as three polymorphisms of MTHFR (677C,T, 1298A,C, and 1793G,A), on endometrial cancer risk among women between the ages of 30 and 69 years in urban Shanghai, China, showed an inverse association of folate intake and risk of endometrial cancer and modufied effects in women ...
The present study is conducted, to elucidate the value of follow-up examinations in endometrial cancer patients. Specifically the objective is to compar
Endometrial cancer is the most common gynaecological cancer in New Zealand and the incidence is increasing as the population ages. Genetic predictors of endometrial cancer risk that allow early detection of the disease are important for prevention and improved management strategies. Mutations in the mismatch repair (MMR) genes MLH1, MSH2, MSH6, PMS1 and PMS2 are known to confer increased risk in a proportion of endometrial cancer cases, and the mutation spectrum includes copy number variants (CNVs). There are several other genes encoding proteins that act in the MMR pathways, but to date the evidence for their involvement in endometrial cancer predisposition is limited. This study aims to 1) To identify genes in the MMR pathway that are overlapped by CNVs in endometrial cancer cases, 2) To compare the CNV frequency of common and rare CNVs between endometrial cancer cases and controls, 3) To identify regions in the genome that are associated with endometrial cancer risk, and 4) To identify ...
3,3′-Diindolylmethane (DIM), a major in vivo product of indole-3-carbinol (I3C), is a promising anticancer agent derived from vegetables of the Brassica genus including broccoli, Brussels sprouts and cabbage. We report here that DIM has a potent cytostatic effect in cultured human Ishikawa endometrial cancer cells. A combination of northern blot and quantitative PCR analyses revealed that DIM induced the level of TGF-α transcripts by ~4-fold within 24 h of indole treatment. DIM also induced a 4-fold increase in the activity of the estrogen response marker, alkaline phosphatase (AP). Co-treatment of cells with the estrogen receptor (ER) antagonist ICI, or with the inhibitor of PKA-mediated activation of the ER, H89, ablated the DIM induction of both TGF-α expression and AP activity. Furthermore, DIM increased the maximum stimulatory effect of estrogen on TGF-α expression. Co-treatment with the protein synthesis inhibitor, cycloheximide, abolished the inductive effects of DIM, indicating ...
Background A patient with early-stage endometrial cancer may possibly have microscopic metastasis in the omentum, which is associated with a poor prognosis. The purpose of this study was to identify...
The overwhelming majority of the patients without endometrial cancer (99 of 109) revealed no or fewer than three genes methylated, whereas all of the 15 endometrial cancer patients had three or more genes methylated in their vaginal secretion (P , 0.001, χ2 test; Fig. 3A). Histological examination of the 10 patients in the no endometrial cancer group with three or more genes methylated revealed invasive cervical cancer (four cases), CIN III (one case), endometrium polyp (four cases), and fibroids (one case). Samples were collected after primary surgery (curettage, punch biopsy of the cervix, or hysteroscopic operation) and before secondary surgery (hysterectomy) in 16 of 124 patients: 9 of 16 patients had endometrial cancer, 3 of 16 patients had CIN III, and 4 of 16 patients had benign disease of the endometrium. All nine endometrial cancer patients had a diagnosis of residual cancer at the time of secondary surgery. All nine endometrial cancer patients had three or more genes methylated, the ...
TY - JOUR. T1 - Update on prognostic markers for endometrial cancer. AU - Binder, Pratibha S.. AU - Mutch, David G.. PY - 2014/5. Y1 - 2014/5. N2 - Endometrial cancer is the most common gynecologic cancer in the USA and the second most common worldwide after cervical cancer. While common symptomatology of endometrial cancer leads to early diagnosis and favorable 5-year survival in most cases, there is a subset of cancers that have a poorer prognosis. The clinical and pathologic prognostic factors for endometrial cancer are well known and instrumental in determining the need for adjuvant therapy. Recently, research has been focused on the identification of molecular changes leading to different histologic subtypes to improve classification of endometrial cancer. The identification of novel mutations and molecular profiles should enhance our ability to personalize adjuvant treatment with genome-guided targeted therapy.. AB - Endometrial cancer is the most common gynecologic cancer in the USA and ...
Endometrial cancer (EC) is a common gynecological cancer. Endometrial cancer (EC) is a common gynecological cancer. The detection of endometrial cancers are ,80% curable in early stage, but dramatic decreasing ,30% of cures in late stage. There 1757 new cases occurred and increased 30% of incidence on 2012 in Taiwan. In addition, the incidents of EC are growing up annually in worldwide and Taiwan. However, no feasible screening method for detecting endometrial cancer. There is an urgent need of biomarkers for detecting endometrial cancer patients. The development of effective methods of detection of EC is also needed. Epigenetic alterations have been shown to occur in many types of cancer. Decades of researches have demonstrated the potential of DNA methylation as a marker for early diagnosis of cancer. The genome-side methylation studies could leads to discover novel genes for detection. We analyzed two methylomics data of endometrial cancers for discovery of novel methylation biomarker using ...
TY - JOUR. T1 - Adjuvant therapy for endometrial cancer. AU - DeLeon, Maria C.. AU - Ammakkanavar, Natraj R.. AU - Matei, Daniela. PY - 2014/1/1. Y1 - 2014/1/1. N2 - Endometrial cancer is a common gynecologic malignancy typically diagnosed at early stage and cured with surgery alone. Adjuvant therapy is tailored according to the risk of recurrence, estimated based on the International Federation of Gynecology and Obstetrics (FIGO) stage and other histological factors. The objective of this manuscript is to review the evidence guiding adjuvant therapy for early stage and locally advanced uterine cancer. For patients with early stage disease, minimizing toxicity, while preserving outstanding cure rates remains the major goal. For patients with locally advanced endometrial cancer optimal combined regimens are being defined. Risk stratification based on molecular traits is under development and may aid refine the current risk prediction model and permit personalized approaches for women with ...
Objective:To explore the relationship between expression of ERRα mRNA and estrogen and progesterone and to elucidate the function of ERRα in endometrial carcinoma. Methods:The expression of ERRα mRNA was examined by reverse transcription polymerase chain reaction. Endometrial carcinoma cell line Ishikawa was dealt with different concentrations of 17β-estradiol(10 -10 mol/L,10 -8 mol/L and 10 -6 mol/L) for 15 min,30 min and 24 h and 17β-estradiol and ER inhibitor-ICI182780 were given concomitantly to observe the change of ERRα mRNA. Different concentrations of progesterone (10 -8 mol/L,10 -7 mol/L,10 -6 mol/L and 10 -5 mol/L)were also given to Ishikawa cell line for 24 h to observe the change of ERRα mRNA. Results:The expression level of ERRα mRNA was slightly higher than that of the control group after being stimulated for 15 min, 30 min and 24 h by 10 -10 mol/L 17β-estradiol. However the expression level of ERRα mRNA was significantly lower than that of
Introduction: Endometrial cancer patients with high grade tumours, deep myometrial invasion or advanced stage disease have a poor prognosis. Randomised studies have demonstrated the prevention of loco-regional relapses with radiotherapy (RT) with no effect on overall survival (OS). The possible additive effect of chemotherapy (CT) remains unclear. Two randomised clinical trials (NSGO-EC-9501/EORTC-55991 and MaNGO ILIADE-III) were undertaken to clarify if sequential combination of chemotherapy and radiotherapy improves progression-free survival (PFS) in high-risk endometrial cancer. The two studies were pooled. Methods: Patients (n = 540; 534 evaluable) with operated endometrial cancer International Federation of Obstetrics and Gynaecology (FIGO) stage I-III with no residual tumour andprognostic factors implying high-risk were randomly allocated to adjuvant radiotherapy with or without sequential chemotherapy. Results: In the NSGO/EORTC study, the combined modality treatment was associated with ...
When endometrial cancer spreads out of its original site, it is called a metastatic endometrial cancer or stage 4 cancer of endometrium. Learn about metastatic endometrial carcinoma, survival rates, treatments, life expectancy.
The fibroblast growth factor receptor (FGF/FGFR) signaling has a significant role in normal organ development, like vascular and skeletal development. The dysregulation of the fibroblast growth receptor signaling occursdue to genetic modification or over expression of the receptor. This has been observed in different carcinomas [34,35].The endometrial carcinoma is the most common gynecologic malignancy in western counties and fourth most common cancer among women worldwide.Type I endometrial carcinomas constitute approximately 70 to 80% of all endometrium cancer.Itfollows estrogens related pathways in carcinogenesis. The BDII rat model is an ideal model for hormonal carcinogenesis because 90% of the female virgin spontaneously develop type I hormone independent endometrial adenocarcinomas within two years of age. Fibroblast growth factor (FGF) ligands via FGFR combined with heparan sulfate proteoglycans (HPSG) in extracellular matrix with the help of proteases and participate in the signal ...
Our objective was to determine if previously reported overall survival (OS) and progression-free survival (PFS) rates are maintained long term following multimodal therapy for advanced and recurrent endometrial cancer and to assess the lymphedema rates associated with this therapy. Women with advanced-stage or recurrent endometrial cancer were recruited between 9/2004 and 6/2009 to our previously published Phase II trial. Patients received intravenous docetaxel (75 mg/m2) and carboplatin (AUC = 6) every 3 weeks for 3 cycles before and after radiation therapy. Patient outcomes were updated in July 2014. Data abstracted included presence of lymphedema, disease progression, and death. OS and PFS estimates at 5 years were calculated using Kaplan-Meier methods. Of the 41 patients enrolled, 10 (24 %) had stage IIIA and 21 (51 %) had stage IIIC disease; 32 (78 %) had endometrioid histology; and 35 (85 %) completed the protocol. With a median follow-up of 5 years, 15 of 41 patients have died. The Kaplan-Meier
Epidermal growth factor (EGF) and its receptor (EGFR) constitute a principal growth-promoting pathway in endometrial cancer cells. Pre-clinical studies were undertaken to compare the expression of EGFR isoforms and the downstream effects of activating or blocking EGFR function in Ishikawa H cells, derived from a moderately differentiated type I endometrioid adenocarcinoma, or in Hec50co cells, derived from a poorly differentiated type II adenocarcinoma with papillary serous sub-differentiation. We investigated whether EGFR mutations are present in the tyrosine kinase domain (exons 18-22) of EGFR and also whether EGFR isoforms are expressed in the Ishikawa H or Hec50co cell lines. Sequence of the EGFR tyrosine kinase domain proved to be wild type in both cell lines. While both cell lines expressed full-length EGFR (isoform A), EGFR and sEGFR (isoform D) were expressed at significantly lower levels in Hec50co cells compared to Ishikawa H cells. Analysis of gene expression following EGF vs. gefitinib
The purpose of this study was to evaluate serum HE4 as a biomarker to detect recurrent disease during follow-up of patients with endometrial adenocarcinoma (EAC). We performed a retrospective analysis of 98 EAC patients treated at Innsbruck Medical University, between 1999 and 2009. Twenty-six patients developed recurrent disease. Median follow-up was 5 years. Serum HE4 and CA125 levels were analyzed using the ARCHITECT assay (Abbott, Wiesbaden, Germany) pre-operatively (baseline), post-operative (interval) and after histological confirmation of recurrent disease or when patients returned for clinical review with no evidence of recurrent disease (recurrence/final)). Receiver operator curves (ROC), Spearman rank correlation coefficient, chi-squared and Mann-Whitney tests were used for statistical analysis. HE4 levels decreased after initial treatment (p = 0.001) and increased again at recurrence (p = 0.002). HE4 was elevated (>70 pmol/L) in 21 of 26 (81%) and CA125 was elevated (>35 U/ml) in 12 of 26 (46
Endometrial cancer is the most common gynecologic malignancy in the United States. An estimated 47,130 women were diagnosed with uterine cancer in 2012, and an estimated 8,010 of these women will die of the disease (1). Type I endometrial cancer account for approximately 80% of cases, are classically of endometrioid histology, and are associated with obesity in up to 90% of cases. In addition, type II diabetes is associated with an increased risk for the development of endometrial cancer (2, 3).. The oral biguanide, metformin, is one of the most commonly used hypoglycemic agents in the management of type II diabetes. Epidemiological studies have demonstrated that diabetic patients being treated with metformin have a reduced cancer incidence or improved response to chemotherapy when compared with patients receiving other oral hypoglycemic agents or insulin (4-6). A meta-analysis of 5 observational studies of all cancer types found that metformin was associated with a 31% decrease in cancer risk ...
On the basis of clinical and pathologic criteria, endometrial carcinoma has been distinguished as types I (mainly endometrioid) and II (nonendometrioid). Limited data suggest that these subtypes have different risk factor profiles. The authors prospectively evaluated risk factors for types I (n = 1,312) and II (n = 138) incident endometrial carcinoma among 114,409 women in the National Institutes of Health (NIH)-AARP Diet and Health Study (1995-2006). For individual risk factors, relative risks were estimated with Cox regression by subtype, and P(heterogeneity) was assessed in case-case comparisons with type I as the referent. Stronger relations for type I versus Type II tumors were seen for menopausal hormone therapy use (relative risk (RR) of 1.18 vs. 0.84; P(heterogeneity) = 0.01) and body mass index of ≥30 vs. |30 kg/m2 (RR of 2.93 vs. 1.83; P(heterogeneity) = 0.001). Stronger relations for type II versus type I tumors were observed for being black versus white (RR of 2.18 vs. 0.66; P
PRIMARY OBJECTIVES:. I. Determine efficacy of single agent cabozantinib-s-malate (cabozantinib) in women previously receiving one line of chemotherapy for metastatic endometrial cancer or with progression within 12 months of completing adjuvant therapy, with co-primary endpoints of objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and progression-free-survival at 12 weeks (PFS).. SECONDARY OBJECTIVES:. I. Correlation of clinical response with baseline molecular status of archival tumor (hepatocyte growth factor receptor [c-met] amplification & mutation status) and overall survival.. OUTLINE:. Patients receive cabozantinib-s-malate orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.. After completion of study treatment, patients are followed up every 4 weeks or every 6 months. ...
Endometrial cancer is the most common gynecologic malignancy. It is the fourth most common cancer in women in the United States after breast, lung, and colorectal cancers. Risk factors are related to excessive unopposed exposure of the endometrium to estrogen, including unopposed estrogen therapy, early menarche, late menopause, tamoxifen therapy, nulliparity, infertility or failure to ovulate, and polycystic ovary syndrome. Additional risk factors are increasing age, obesity, hypertension, diabetes mellitus, and hereditary nonpolyposis colorectal cancer. The most common presentation for endometrial cancer is postmenopausal bleeding. The American Cancer Society recommends that all women older than 65 years be informed of the risks and symptoms of endometrial cancer and advised to seek evaluation if symptoms occur. There is no evidence to support endometrial cancer screening in asymptomatic women. Evaluation of a patient with suspected disease should include a pregnancy test in women of childbearing age
Loss of heterozygosity of chromosome 10q has been reported in approximately 40% of endometrial carcinomas. PTEN, a candidate tumor suppressor gene located at chromosome 10q23.3, was recently identified and found to be homozygously deleted or mutated in several different types of human tumors. To determine if PTEN is a target of 10q loss of heterozygosity in carcinomas of the endometrium, we examined 32 primary endometrial carcinomas for mutations in PTEN. The tumors included the two major histopathological types of endometrial carcinoma: endometrioid (n = 26; 14 microsatellite instability (MI)-positive and 12 MI-negative) and serous (n = 6). Overall, mutations were detected in 50% of the endometrial carcinomas we analyzed. Mutations were present in 12 of 14 (86%) MI-positive and 4 of 12 (33%) MI-negative endometrioid tumors. Furthermore, mutations were found in all three histological grades of MI-positive endometrioid carcinoma. All six serous endometrial carcinomas lacked detectable mutations. ...
In this study, women with the A2 allele of CYP17 were at decreased risk of endometrial cancer. Among postmenopausal women, we did not detect strong associations between CYP17 genotype and circulating steroid hormone levels. We did observe a significant interaction between CYP17 genotype and first-degree family history of endometrial and colorectal cancer, but we did not observe the endometrial cancer risk that is associated with CYP17 genotype to be substantially altered by other established hormone-related endometrial cancer risk factors.. The established risk factors for endometrial cancer are understood to act by altering chronic estrogen exposure unopposed by progesterone (3) . Likewise, the hypothesized mechanism through which genetic variation in CYP17 may influence endometrial cancer risk is by altering a womans lifetime exposure to endogenous steroid hormones. On the basis of the enzymatic steps catalyzed by CYP17, we would expect carriers of one or two A2 alleles to have elevated ...
OBJECTIVES : The purpose of this study was to evaluate the effect of cigarette smoking and alcohol use on the risk of endometrial cancer. The impact of smoking on serum estrone, estradiol, and androstenedione levels also was examined. STUDY DESIGN : This hospital-based case-control study included 168 women with endometrial carcinoma and 334...
This pilot clinical trial studies how well dasatinib works together with paclitaxel and carboplatin in treating patients with stage III, stage IV or rec
Prolonged excessive estrogen exposure unopposed by progesterone is widely accepted to be a risk factor for endometrial cancer development. The physiological function of progesterone is dependent upon the presence of its receptor [progesterone receptor (PGR)] and several studies have reported single nucleotide polymorphisms (SNPs) in the PGR gene to be associated with endometrial cancer risk. We sought to confirm the associations with endometrial cancer risk previously reported for four different PGR polymorphisms. A maximum of 2888 endometrial cancer cases and 4483 female control subjects from up to three studies were genotyped for four PGR polymorphisms (rs1042838, rs10895068, rs11224561 and rs471767). Logistic regression with adjustment for age, study, ethnicity and body mass index was performed to calculate odds ratios (ORs) and associated 95% confidence intervals (CIs) and P-values. Of the four SNPs investigated, only rs11224561 in the 3′ region of the PGR gene was found to be ...
Tamoxifen resistance and tamoxifen-induced endometrial proliferation are major limitations of tamoxifen therapy and chemoprevention. The present study shows that MSA inhibition of ERα signaling is not restricted to tamoxifen-sensitive MCF-7 cells. MSA antagonism of estradiol-dependent ERE2e1b-luciferase and endogenous c-myc and pS2 gene expression was shown in MCF-7-LCC2 cells, an ERα-positive, tamoxifen-resistant variant of the MCF-7 parental line and in two ERα-positive human endometrial cancer cell lines, Ishikawa and HEC1A (Figs. 1 and 2). In addition, MSA also blocked tamoxifen activation of these genes in endometrial Ishikawa and HEC1A cells (Fig. 1 and Fig. 2C-D, column 6). The major mechanism for MSA disruption of ER signaling in all ERα-positive cells lines was via rapid decrease of ERα mRNA and protein that preceded disruption of ERα-regulated gene expression (Figs. 3 and 4). MSA alone inhibited the growth of tamoxifen-sensitive, tamoxifen-resistant and endometrial-derived cells. ...
TY - JOUR. T1 - Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy. AU - Ikeda, Yuji. AU - Oda, Katsutoshi. AU - Ishihara, Hideki. AU - Wada-Hiraike, Osamu. AU - Miyasaka, Aki. AU - Kashiyama, Tomoko. AU - Inaba, Kanako. AU - Fukuda, Tomohiko. AU - Sone, Kenbun. AU - Matsumoto, Yoko. AU - Arimoto, Takahide. AU - Maeda, Daichi. AU - Ikemura, Masako. AU - Fukayama, Masahi. AU - Kawana, Kei. AU - Yano, Tetsu. AU - Aoki, Daisuke. AU - Osuga, Yutaka. AU - Fujii, Tomoyuki. PY - 2015/11/17. Y1 - 2015/11/17. N2 - Background:Pathologically low-risk endometrial cancer patients do not receive postoperative treatment; however, 10-15% of these patients show recurrence with poor prognosis. We evaluated the clinical importance of cyclin-dependent kinase 4/6 (CDK4/6) activity, and its significance as a novel biomarker for the prognosis and chemo-sensitivity of endometrioid endometrial carcinoma ...
They grow in response to excess oestrogen, or in other words oestrogen dominance, where the natural progesterone is not being balanced by the oestrogen in the body. Also, your doctor may advise that you not use tampons or have sexual intercourse during recovery. Although I have a history of fibroids - for which I was treated with a fibroid embolization type surgery which essencially killed all of my active fibroids... fibroids and pregnancy diet plan et al 14 transplanted both ER-positive and ER-negative human endometrial cancer cell lines into nude mice and evaluated the effect of both tamoxifen and 17-beta-estradiol on tumor growth.
Endometrial cancer is the most frequently occurring malignancy of the female genital tract in Western countries. Although in many cases surgically curable, about 30% of the tumours represent an aggressive and untreatable disease. In an attempt to establish a reliable prognostic marker for endometrial carcinomas disregarding their histological diversity, we investigated the expression of KPNA2, a mediator of nucleocytoplasmic transport, and other cell proliferation-associated proteins and their correlation with cancer progression. We analysed patient tissue microarrays (TMAs) assembled from 527 endometrial cancer tissue specimens and uterus samples from a Trp53 knockout mouse model of endometrial cancer. Our data show that KPNA2 expression was significantly up-regulated in human endometrial carcinomas and associated with higher tumour grade (p = 0.026), higher FIGO stage (p = 0.027), p53 overexpression (p , 0.001), activation of the PI3K/AKT pathway, and epithelial-mesenchymal transition. ...
TY - JOUR. T1 - Transforming growth factor β signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition. AU - Parekh, Trilok V.. AU - Gama, Patricia. AU - Wen, Xie. AU - Demopoulos, Rita. AU - Munger, John S.. AU - Carcangiu, Maria Luisa. AU - Reiss, Michael. AU - Gold, Leslie I.. PY - 2002/5/15. Y1 - 2002/5/15. N2 - Transforming growth factor β (TGF-β), a potent ubiquitous endogenous inhibitor of epithelial cell growth, is secreted as a latent molecule (LTGF-β) requiring activation for function. TGF-β signals through the type I (TβRI) and type II (TβRII) receptors, which cooperate to phosphorylate/activate Smad2/3, the transcriptional regulators of genes that induce cell cycle arrest. That carcinomas grow in vivo suggests that they are refractory to TGF-β. However, this has been difficult to prove because of an inability to analyze the functional status of TGF-β in vivo as well as lack of close physiological paradigms for carcinoma cells ...
Gynecological malignancies (ovarian clear cell and endometrioid carcinomas, endometrial serous, endometrioid and clear cell carcinomas) harbor somatic mutations in the gene PPP2R1A, the scaffolding subunit of the serine/threonine protein phosphatase 2A (PP2A) complex. The PP2A complex is composed of an A (scaffold), C (catalytic) subunit, and different B (regulatory) subunits. The PPP2R1A mutations are proposed to play a role in PP2A B-subunit binding, and thus formation of a functional PP2A phosphatase complex. The aim of this study is to determine how PPP2R1A mutations affect the binding of B-subunits and other novel interactions within the context of ovarian and endometrial carcinomas.. The ovarian clear cell line RMG2 and endometrial carcinoma cell lines Hec-1-A and Hec50 all harbor PPP2R1A mutations. The mismatch repair deficient cell line Hec-1-A express a PPP2R1A W257L heterozygous mutation; therefore somatic cell knockout technology was used to generate isogenic PPP2R1A clones that ...
Liao, QP,Wu, C,Zheng, H. Expression of estrogen and progesterone receptor subtypes in human endometrial carcinoma.[J]. JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION,2004,suppl.S(2):406A-406A ...
The lining of the uterus is called the endometrium. Cancer of the endometrium, the most common cancer of the female reproductive organs, is a disease in which malignant (cancerous) cells are found in the endometrium.. About 75 percent of all endometrial cancers are adenocarcinomas. Endometrial cancer is highly curable when found early, according to the American Cancer Society (ACS).. The exact cause of endometrial cancer is not known, and there is no medical cure for it at this time. However, physicians believe that avoiding the known risk factors, when possible, using oral contraceptives, controlling obesity, and controlling diabetes are the best ways to lower the risk of developing endometrial cancer.. Symptoms of endometrial cancer may include bleeding or discharge not related to menstruation, post-menopausal bleeding, difficult or painful urination, and pain during intercourse. Other symptoms such as pain and/or mass in the pelvic area and weight loss could also be a sign.. Endometrial ...
TY - JOUR. T1 - High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. AU - Kacinski, Barry M.. AU - Carter, Darryl. AU - Mittal, Khushbakhat. AU - Kohorn, Ernest I.. AU - Bloodgood, R. Shaeffer. AU - Donahue, John. AU - Donofrio, Lisa. AU - Edwards, Rob. AU - Schwartz, Peter E.. AU - Chambers, Joseph T.. AU - Chambers, Setsuko K.. PY - 1988. Y1 - 1988. N2 - Six micron paraffin sections of paraformaldehyde-fixed endometrial currettings of 21 benign and neoplastic endometrial specimens were assayed for tumor cell-specific oncogene expression by in situ hybridization with probes for six oncogenes, beta-actin, and the E. coli plasmid pBR322. In the benign hyperplasias and invasive adenocarcinomas, multiple oncogenes, including erbB, fms, c-myc, and Ki-ras were expressed at significant levels. For the adenocarcinomas, statistical analysis demonstrated that high levels of expression of fms-complementary mRNA correlated strongly with ...
Endometrial cancer is one of the leading gynecological malignant tumor occurring in women in their menopausal and postmenopausal age. In polish population its incidence rate takes the fourth position among other cancer related diseases. The total number of new cases has doubled since the last three decades as it is observed in Poland. Due to the progressive ageing of the polish society, the substantial increase of endometrial cancer incidence rate in the near future may be expected. The current clinico-pathological classification of endometrial cancer includes two types, i.e., type I - endometrioid and type II nonendometrioid cancers. Endometrial cancer type I is mostly diagnosed as endometrial adenocarcinoma with 75%-85% incidence. Despite favorable prognosis for the patients with endometrial cancer its related morbidity is strongly associated with diagnosed cancer aggressiveness. Thus, in the case of cancers classified as FIGO I stage it is about 20%, whereas in the most advanced stage FIGO IV ...
International Scholarly Research Notices is a peer-reviewed, Open Access journal covering a wide range of subjects in science, technology, and medicine. The journals Editorial Board as well as its Table of Contents are divided into 108 subject areas that are covered within the journals scope.
Obesity, a major risk factor for endometrial cancer, is a low-grade inflammatory state characterized by elevated concentrations of cytokines and acute phase reactants. The current study had two aims: first to investigate the associations of C-reactive protein (CRP), interleukin 6 (IL6), and IL1 receptor antagonist (IL1Ra) with endometrial cancer risk and second to examine to which extent these markers can influence the association between obesity and endometrial cancer. We conducted a case-control study, nested within the European Prospective Investigation into Cancer and Nutrition, which comprised 305 incident cases of endometrial cancer and 574 matched controls. CRP, IL6, and IL1Ra were measured in prospectively collected blood specimens by immunoassays. Data were analyzed using conditional logistic regression. All statistical tests were two-sided, and P values |0.05 were considered statistically significant. We observed a significant increase in risk of endometrial cancer with elevated levels of CRP
Cancer of the womb (uterus) is the most common cancer affecting the female reproductive system in the developed world. Most womb cancers arise from abnormal growth of the womb lining (endometrium) and are termed endometrial cancer. Endometrial hyperplasia is a thickening of the womb lining, which can progress to endometrial cancer, if untreated. Worldwide, endometrial cancer affects 382,000 women per year (Globocan 2019), including over 9000 women in the UK. Its incidence rates have increased by almost three-fifths (57%) in the UK since the early 1990s, with similar trends reported globally (Lortet-Tieulent 2018). Most women diagnosed with endometrial cancer are postmenopausal; 93% of those diagnosed in the UK between 2014 and 2016 were over the age of 50 (CRUK 2019). Increasingly, however, a greater number of younger premenopausal women are being diagnosed with the disease (Unzurrunzaga 2019).. Most of the increase in incidence is due to low-grade Type 1 cancers. These are largely caused by an ...
... !DOCTYPE html PUBLIC -//W3C//DTD XHTML 1.0 Transitional//EN http:... Encouraging trend observed in overall survival with limited side-e... The safety and efficacy of AEZS-108 in our study on advanced endomet...Juergen Engel Ph.D. President and CEO of Aeterna Zentaris added W...,Aeterna,Zentaris,Presents,Positive,Phase,2,Efficacy,and,Safety,Data,for,AEZS-108,in,Advanced,Endometrial,Cancer,at,ENA,Meeting,in,Berlin,,Germany,biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology
TY - JOUR. T1 - Regular analgesic use and risk of endometrial cancer. AU - Moysich, Kirsten B.. AU - Baker, Julie A.. AU - Rodabaugh, Kerry J.. AU - Villella, Jeannine A.. PY - 2005/12. Y1 - 2005/12. N2 - Background: Analgesic use has been implicated in the chemoprevention of a number of solid tumors, but thus far, no previous research has focused on the role of aspirin in endometrial cancer etiology. Methods: We conducted a hospital-based case-control study of 427 women with primary, incident endometrial cancer, and 427 age- and residence-matched controls without benign or malignant neoplasms. All participants received medical services at Roswell Park Cancer Institute in Buffalo, NY, and completed a comprehensive epidemiologic questionnaire. Women who reported analgesic use at least once a week for at least 6 months were classified as regular users and served as the reference group throughout the analyses. We used unconditional logistic regression analyses to compute crude and adjusted odds ...
QUÉBEC CITY, Feb. 4, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that an article on Phase 2 results for zoptarelin doxorubicin (AEZS-108) in endometrial cancer has been published in the February issue of the International Journal of Gynecological Cancer. Zoptarelin doxorubicin, is the Companys cytotoxic peptide conjugate which specifically targets luteinizing hormone-releasing hormone ("LHRH") receptors. The article, "Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)", Emons G., Gorchev G., Harter P., Wimberger P., Stähle A., Hanker L., Hilpert F., Beckmann M.W., Dall P., Gründker C., Sindermann H., Sehouli J., outlines results of this study which had been previously presented at the European Society of Gynaecological Oncologys ("ESGO") annual meeting in September 2011. The article is currently ...
Endometrial cancer is the most common gynecologic cancer, but there has been little consensus about the appropriate indications for adjuvant therapy. One reason for the lack of consensus is the absence of randomized studies in endometrial cancer that report an overall survival benefit. This may be attributed to the frequency of comorbidities in women with endometrial cancer, which increases the risk of death from causes other than cancer. Furthermore, many trials have "lumped" patients with diverse risk factors, raising questions about the applicability of study findings to subsets of patients meeting the eligibility criteria.. Despite these limitations, there have been many large studies conducted in endometrial cancer that provide insights into the best treatment recommendations to improve disease-free survival and quality of life. ASTRO developed evidence-based guidelines on the role of postoperative adjuvant therapy in endometrial cancer as a resource for the oncology community.1 In July ...
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
Endometrial Tumor Tissue Array - Duplicated 70 cases of endometrial cancer and 5 cases of normal and other non-malignan, Human Tissue Array - Endometrial Tumor (70 cases + 5 normal), GTX21466, Applications: IHC-P, ISH; IHC (Formalin-fixed paraffin-embedded sections), In situ hybridization; CrossReactivity:
HE4, also known as WFDC2, is a useful biomarker for ovarian cancer when either used alone or in combination with CA125. HE4 is also overexpressed in endometrial cancer (EC), but its function in cancer cells is not clear. In this study, we investigate the role of HE4 in EC progression. An HE4-overexpression system was established by cloning the HE4 prototypic mRNA variant (HE4-V0) into a eukaryotic expression vector. Following transfection, stable clones in two EC cell lines were selected. The effects of HE4 overexpression on cell growth and function were measured with the use of cell proliferation assay, matrigel invasion, and soft agar gel colony formation assays. HE4-induced cancer cell proliferation in vivo was examined in a mouse xenograft model. HE4 overexpression significantly enhanced EC cell proliferation, matrigel invasion, and colony formation in soft agar. Moreover, HE4 overexpression promoted tumor growth in the mouse xenograft model. HE4 overexpression enhanced several malignant phenotypes
TY - JOUR. T1 - In vitro sensitivity of human endometrial cancer to cytotoxic and biologic agents.. AU - Welander, C. E.. AU - Jones, C. M.. AU - Alberts, David S. AU - Salmon, S. E.. PY - 1989. Y1 - 1989. UR - http://www.scopus.com/inward/record.url?scp=0024797185&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0024797185&partnerID=8YFLogxK. M3 - Article. C2 - 2577199. AN - SCOPUS:0024797185. VL - 49. SP - 117. EP - 126. JO - Cancer Treatment and Research. JF - Cancer Treatment and Research. SN - 0927-3042. ER - ...
An Autumn Peach Reviewing my past year with uterine (endometrial) cancer, I am grateful for and thank everyone for their support. Also wishing my sisters with all gynecologic and breast cancers the very best this fall season. October 10, 2013: A year ago today, my reading group met to discuss The Book Thief by Markus Zusak,…